Potassium-competitive acid blockers and acid-related disorders.

Journal

Current opinion in endocrinology, diabetes, and obesity

ISSN: 1752-2978

Titre abrégé: Curr Opin Endocrinol Diabetes Obes

Pays: England

ID NLM: 101308636

Informations de publication

Date de publication:
15 Mar 2024

Historique:

medline: 14 3 2024

pubmed: 14 3 2024

entrez: 14 3 2024

Statut: aheadofprint

Résumé

Potassium-competitive acid blockers (PCABs) represent a new class of compounds for the treatment of acid-related disorders. Recent FDA approval of the PCAB vonoprazan for erosive esophagitis has started an important new approach to acid-related disorders. Compared to conventional proton pump inhibitors (PPIs), PCABs provide more rapid, potent, and sustained suppression of gastric acid with faster and more durable symptom relief. Studies have demonstrated the efficacy of PCABs for erosive esophagitis, nonerosive reflux disease, and peptic ulcer disease including H. pylori. However, the PCAB vonoprazan was only approved in the US as part of combination therapy for eradication of H. pylori. Clinical trials have now demonstrated noninferiority of vonoprazan to lansoprazole for treatment of erosive esophagitis, particularly noting superiority of vonoprazan in patients with severe esophagitis resulting in FDA approval of vonoprazan for treatment of erosive esophagitis. Emerging data suggests a possible utility of vonoprazan for PPI-resistant gastroesophageal reflux disease (GERD) and on-demand therapy for nonerosive reflux disease. Vonoprazan is generally well tolerated but long-term safety data is not well established. The PCAB vonoprazan is a newly FDA approved treatment option for erosive esophagitis. Its possible role in PPI-resistant GERD and nonerosive reflux disease warrants further investigation.

Identifiants

DOI: 10.1097/MED.0000000000000858 PMID: 38483115

pubmed: 38483115

doi: 10.1097/MED.0000000000000858

pii: 01266029-990000000-00089

doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Informations de copyright

Références

Strand DS, Kim D, Peura DA. 25 Years of proton pump inhibitors: a comprehensive review. Gut Liver 2017; 11:27–37.

Drugs for GERD and peptic ulcer disease. Med Lett Drugs Ther 2022; 64:49–56.

Katz PO, Dunbar K, Schnoll-Sussman FH, et al. ACG clinical guideline: guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol 2022; 117:27–56.

Freedberg DE, Kim LS, Yang YX. The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association. Gastroenterology 2017; 152:706–715.

Yibirin M, De Oliveira D, Valera R, Plitt AE, Lutgen S. Adverse effects associated with proton pump inhibitor use. Cureus. 13:e12759. doi:10.7759/cureus.12759.

Scarpignato C, Tolone S. Addressing long-term PPI safety. Dig Liver Dis 2020; 52:853–856.

Garnock-Jones KP. Vonoprazan: first global approval. Drugs 2015; 75:439–443.

Vonoprazan (Voquezna) for erosive esophagitis. Med Lett Drugs Ther 2023; 65:203–205.

Wong N, Reddy A, Patel A. Potassium-Competitive Acid Blockers: Present and Potential Utility in the Armamentarium for Acid Peptic Disorders. Gastroenterol Hepatol (N Y) 2022; 18:693–700.

Abdel-Aziz Y, Metz DC, Howden CW. Review article: potassium-competitive acid blockers for the treatment of acid-related disorders. Aliment Pharmacol Ther 2021; 53:794–809.

Engevik AC, Kaji I, Goldenring JR. The physiology of the gastric parietal cell. Physiol Rev 2020; 100:573–602.

National Center for Biotechnology Information (US), Dean L, Kane M. Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kattman BL, Malheiro AJ. Omeprazole therapy and CYP2C19 genotype. Medical genetics summaries 2024.

Kagami T, Sahara S, Ichikawa H, et al. Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype. Aliment Pharmacol Ther 2016; 43:1048–1059.

Rawla P, Sunkara T, Ofosu A, Gaduputi V. Potassium-competitive acid blockers – are they the next generation of proton pump inhibitors? World J Gastrointest Pharmacol Ther 2018; 9:63–68.

Kang C. Keverprazan hydrochloride: first approval. Drugs 2023; 83:639–643.

Scott DR, Sachs G, Marcus EA. The role of acid inhibition in Helicobacter pylori eradication. F1000Research 2016; 5:1747.

Chey WD, Mégraud F, Laine L, et al. Vonoprazan triple and dual therapy for helicobacter pylori infection in the United States and Europe: randomized clinical trial. Gastroenterology 2022; 163:608–619.

Two vonoprazan combinations (Voquezna) for H. pylori. Med Lett Drugs Ther 2022; 64:169–172.

Chiu YT, Lee FJ, Kuo CY, et al. Seven-day vonoprazan-based triple therapy as first-lineHelicobacter pylori treatment in comparison with extended sequential therapy. JGH Open Access J Gastroenterol Hepatol 2023; 7:105–109. doi: 10.1002/jgh3.12858.

doi: 10.1002/jgh3.12858

Kato M, Ota H, Okuda M, et al. Guidelines for the management of Helicobacter pylori infection in Japan: 2016 revised edition. Helicobacter 2019; 24:e12597.

Simadibrata DM, Syam AF, Lee YY. A comparison of efficacy and safety of potassium-competitive acid blocker and proton pump inhibitor in gastric acid-related diseases: a systematic review and meta-analysis. J Gastroenterol Hepatol 2022; 37:2217–2228.

Ashida K, Sakurai Y, Hori T, et al. Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther 2016; 43:240–251.

Xiao Y, Zhang S, Dai N, et al. Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis. Gut 2020; 69:224–230.

Laine L, DeVault K, Katz P, et al. Vonoprazan versus lansoprazole for healing and maintenance of healing of erosive esophagitis: a randomized trial. Gastroenterology 2023; 164:61–71.

Yadlapati R, Hubscher E, Pelletier C, et al. Induction and maintenance of healing in erosive esophagitis in the United States. Expert Rev Gastroenterol Hepatol 2022; 16:967–980.

Zhuang Q, Chen S, Zhou X, et al. Comparative efficacy of P-CABs versus proton pump inhibitors for Grade C/D esophagitis: a systematic review and network meta-analysis. Am J Gastroenterol 2024; doi: 10.14309/ajg.0000000000002714. [Epub ahead of print]. PMID: 38345252.

doi: 10.14309/ajg.0000000000002714.

Simadibrata DM, Lesmana E, Fass R. Vonoprazan is superior to lansoprazole for healing of severe but not mild erosive esophagitis: a systematic review with meta-analysis of randomized controlled trials. J Gastroenterol Hepatol 2024; doi: 10.1111/jgh.16486. [Epub ahead of print]. PMID: 38353152.

doi: 10.1111/jgh.16486.

Martinez SD, Malagon IB, Garewal HS, et al. Nonerosive reflux disease (NERD) — acid reflux and symptom patterns. Aliment Pharmacol Ther 2003; 17:537–545.

Kahrilas PJ, Boeckxstaens G, Smout AJ. Management of the patient with incomplete response to PPI therapy. Best Pract Res Clin Gastroenterol 2013; 27:401–414.

Dean BB, Gano AD, Knight K, et al. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2004; 2:656–664.

Kinoshita Y, Sakurai Y, Shiino M, et al. Evaluation of the efficacy and safety of vonoprazan in patients with nonerosive gastroesophageal reflux disease: a phase III, randomized, double-blind, placebo-controlled, multicenter study. Curr Ther Res Clin Exp 2016; 81-82:1–7.

Kinoshita Y, Sakurai Y, Takabayashi N, et al. Efficacy and safety of vonoprazan in patients with nonerosive gastroesophageal reflux disease: a randomized, placebo-controlled, phase 3 study. Clin Transl Gastroenterol 2019; 10:e00101.

Kim SH, Cho KB, Chun HJ, et al. Randomised clinical trial: comparison of tegoprazan and placebo in nonerosive reflux disease. Aliment Pharmacol Ther 2021; 54:402–411.

Hamada S, Ihara E, Ikeda H, et al. Clinical characterization of vonoprazan-refractory gastroesophageal reflux disease. Digestion 2019; 102:197–204.

Tack J, Vladimirov B, Horny I, et al. Randomized clinical trial: a double-blind, proof-of-concept, phase 2 study evaluating the efficacy and safety of vonoprazan 20 or 40 mg versus esomeprazole 40 mg in patients with symptomatic gastro-esophageal reflux disease and partial response to a healing dose of a proton-pump inhibitor. Neurogastroenterol Motil 2023; 35:e14468.

Simadibrata DM, Lesmana E, Fass R. A systematic review and meta-analysis of the efficacy of vonoprazan for proton pump inhibitor-resistant gastroesophageal reflux disease. J Gastroenterol Hepatol 2024; doi: 10.1111/jgh.16475. Epub ahead of print. PMID: 38263507.

doi: 10.1111/jgh.16475.

Hoshikawa Y, Kawami N, Hoshino S, et al. Efficacy of on-demand therapy using 20-mg vonoprazan for nonerosive reflux disease. Esophagus 2019; 16:201–206.

Fass R, Vaezi M, Sharma P, et al. Randomised clinical trial: efficacy and safety of on-demand vonoprazan versus placebo for nonerosive reflux disease. Aliment Pharmacol Ther 2023; 58:1016–1027.

Kagawa T, Iwamuro M, Ishikawa S, et al. Vonoprazan prevents bleeding from endoscopic submucosal dissection-induced gastric ulcers. Aliment Pharmacol Ther 2016; 44:583–591.

Hidaka Y, Imai T, Inaba T, et al. Efficacy of vonoprazan against bleeding from endoscopic submucosal dissection-induced gastric ulcers under antithrombotic medication: a cross-design synthesis of randomized and observational studies. PLoS One 2021; 16:e0261703.

Kuzumoto T, Tanaka F, Sawada A, et al. Vonoprazan shows efficacy similar to that of proton pump inhibitors with respect to symptomatic, endoscopic, and histological responses in patients with eosinophilic esophagitis. Esophagus 2021; 18:372–379.

Franciosi JP, Mougey EB, Dellon ES, et al. Proton pump inhibitor therapy for eosinophilic esophagitis: history, mechanisms, efficacy, and future directions. J Asthma Allergy 2022; 15:281–302.

Moraes-Filho JPP, Domingues G, Chinzon D, et al. Vonoprazan in the management of gastric/peptic ulcers: a systematic review of safety data. Przeglad Gastroenterol 2022; 17:266–273.

Cheung KS, Leung WK. Long-term use of proton-pump inhibitors and risk of gastric cancer: a review of the current evidence. Ther Adv Gastroenterol 2019; 12:175628481983451.

Haruma K, Kinoshita Y, Yao T, et al. Randomised clinical trial: 3-year interim analysis results of the VISION trial to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive oesophagitis. BMC Gastroenterol 2023; 23:139.

Arai J, Hayakawa Y, Niikura R, et al. Letter: Potassium-competitive acid blockers may increase the risk of gastric cancer after Helicobacter pylori eradication a retrospective multicentre-cohort analysis. Aliment Pharmacol Ther 2023; 57:1196–1198.